<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445831</url>
  </required_header>
  <id_info>
    <org_study_id>ACI-35-1802</org_study_id>
    <secondary_id>2018-004573-27</secondary_id>
    <nct_id>NCT04445831</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease</brief_title>
  <official_title>A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Immune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research and Development LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AC Immune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate
      the safety, tolerability and immunogenicity of different doses, regimens and combinations of
      Tau targeted vaccines in participants with early Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related)</measure>
    <time_frame>from screening up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in anti-phosphorylated Tau IgG titers in blood</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in systolic and diastolic blood pressure (mmHg)</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in heart rate (bpm)</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in body temperature (degree Celsius)</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal MRI results</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-Tau IgG titers in blood</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-phosphorylated Tau IgM titers in blood</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-Tau IgM titers in blood</measure>
    <time_frame>from baseline up to week 74</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline of functional performance using Clinical Dementia Rating scale Sum of Boxes (CDR-SB)</measure>
    <time_frame>from baseline up to week 74</time_frame>
    <description>The score ranges from 0 to 18. A higher score indicates a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of cognitive performance using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>from baseline up to week 74</time_frame>
    <description>The total scale index score ranges from 40 to 160. A higher score indicates a better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of behavior using Neuropsychiatric Inventory Scale (NPI)</measure>
    <time_frame>from baseline up to week 74</time_frame>
    <description>The score ranges from 0 to 144. A higher score indicates a worse outcome.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Tauopathies</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered at predefined time points over a 48-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACI-35.030 - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine administered at predefined time points over a 48-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACI-35.030 - Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine administered at predefined time points over a 48-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACI-35.030 - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active vaccine administered at predefined time points over a 48-week period (optional).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACI-35.030</intervention_name>
    <description>Administration of a Low dose of ACI-35.030</description>
    <arm_group_label>ACI-35.030 - Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACI-35.030</intervention_name>
    <description>Administration of a Medium dose of ACI-35.030</description>
    <arm_group_label>ACI-35.030 - Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACI-35.030</intervention_name>
    <description>Administration of a High dose of ACI-35.030 (optional)</description>
    <arm_group_label>ACI-35.030 - High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female with age from 50 and up to 75 years old inclusive.

          2. Mild AD or Mild Cognitive Impairment (MCI) due to AD according to NIA-AA criteria.

          3. Mini Mental State Examination (MMSE) score of 22 or above.

          4. Levels of CSF Amyloid Beta 42 (AÃŸ42) and phosphorylated Tau at screening consistent
             with NIA-AA 2018 criteria for AD pathology.

          5. Subjects either not taking any marketed treatment for AD or receiving a stable dose of
             an acetylcholinesterase inhibitor and/or memantine for at least 3 months prior to
             baseline.

          6. Subjects cared for by a reliable informant or caregiver to assure compliance, assist
             with clinical assessments and report safety issues.

          7. Women must be post-menopausal for at least one year and/or surgically sterilized.

          8. Subjects who in the opinion of the investigator is able to understand and provide
             written informed consent.

          9. Both subject and informant or caregiver must be fluent in one of the languages of the
             study and able to comply with all study procedures, including lumbar punctures.

        Exclusion criteria:

          1. Participation in previous clinical trials for AD and/or for neurological disorders
             using active immunization unless there is documented evidence that the subject was
             treated with placebo only and the placebo vaccine is not expected to induce any
             specific immune response.

          2. Participation in previous clinical trials for AD and/or for neurological disorders
             using any passive immunization within the past 12 months prior to screening.

          3. Participation in previous clinical trials for AD and/or for neurological disorders
             using any small molecule drug including BACE-1 inhibitors within the past 3 months
             prior to screening.

          4. Concomitant participation in any other clinical trial using experimental or approved
             medications or therapies.

          5. Presence of positive Anti-nuclear Antibody (ANA) titers at a dilution of at least
             1:160 in subjects without clinical symptoms of auto-immune disease.

          6. Current or past history of auto-immune disease, or clinical symptoms consistent with
             the presence of auto-immune disease.

          7. Immune suppression including but not limited to the use of immunosuppressive drugs or
             systemic steroids unless they have been prescribed transiently more than 3 months
             prior to screening.

          8. History of severe allergic reaction (e.g., anaphylaxis) including but not limited to
             severe allergic reaction to previous vaccines and/or medications.

          9. Prior history of clinically significant hypoglycaemic episodes.

         10. Drug or alcohol abuse or dependence currently met or within the past five years
             according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) criteria.

         11. Any clinically significant medical condition likely to interfere with the evaluation
             of safety and tolerability of the study treatment and/or the adherence to the full
             study visit schedule.

         12. Any clinically significant medical condition likely to impact the immune system (e.g,
             any history of acquired or innate immune system disorder).

         13. Use of hydralazine, procainamide, quinidine, isoniazide, TNF-inhibitors, minocycline
             within the last 12 months prior to screening.

         14. Use of diltiazem unless on a stable dose for at least 3 months prior to screening.

         15. Significant risk of suicide defined, using the Columbia-Suicide Severity Rating Scale,
             as the subject answering: &quot;yes&quot; to suicidal ideation questions 4 or 5 or answering:
             &quot;yes&quot; to suicidal behavior within the past 12 months.

         16. Concomitant psychiatric or neurologic disorder other than those considered to be
             related to AD.

         17. History or presence of uncontrolled seizures.

         18. History of meningoencephalitis within the past 10 years prior to screening.

         19. Subjects with a history of hemorrhagic and/or non-hemorrhagic stroke.

         20. Presence or history of peripheral neuropathy.

         21. History of inflammatory neurological disorders with potential for CNS involvement.

         22. Screening MRI scan showing structural evidence of alternative pathology not consistent
             with AD which could cause the subject's symptoms.

         23. MRI examination cannot be done for any reason, including but not limited to metal
             implants contraindicated for MRI studies and/or severe claustrophobia.

         24. Significant hearing or visual impairment or other issues judged relevant by the
             investigator preventing to comply with the protocol and to perform the outcome
             measures.

         25. Clinically significant infections or major surgical operation within 3 months prior to
             screening.

         26. Any vaccine received within the past 2 weeks before screening, including influenza
             vaccine.

         27. Clinically significant arrhythmias or other clinically significant abnormalities on
             ECG at screening.

         28. Myocardial infarction within one year prior to baseline, unstable angina pectoris, or
             significant coronary artery disease.

         29. History of cancer within the past 5 years other than treated squamous cell carcinoma,
             basal cell carcinoma and melanoma in situ, or in-situ prostate cancer or in-situ
             breast cancer which have been fully removed and are considered cured.

         30. Clinically significant deviations from normal values for hematologic parameters, liver
             function tests, and other biochemical measures, that are judged to be clinically
             significant in the opinion of the investigator.

         31. Pregnancy confirmed by blood test at screening, or subject planning to be pregnant or
             lactating.

         32. Receipt of any anticoagulant drug or antiplatelet drug, except aspirin at doses of 100
             mg daily or lower.

         33. Receipt of any antipsychotic drugs except at low doses for the treatment of insomnia.

         34. Donation of blood or blood products within 30 days prior to screening or plans to
             donate blood while participating in the study.

         35. Positive Venereal Disease Research Laboratory (VDRL) consistent with active syphilis
             at screening.

         36. Positive HIV test at screening.

         37. Laboratory or clinical evidence of active hepatitis B and/or C at screening.

         38. Serum creatinine greater than 1.5x upper limit of normal, abnormal thyroid function
             tests or clinically significant reduction in serum B12 or folate levels.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Scheltens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam UMC Alzheimer Center de Boelelaan Amsterdam The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Sol, MD</last_name>
    <phone>+41 21 345 9121</phone>
    <email>clinicaltrials@acimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benedicte Le</last_name>
    <phone>+41 21 345 9121</phone>
    <email>clinicaltrials@acimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ItÃ¤-Suomen Yliopisto - Kuopion Kampus</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Merja Hallikainen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Services Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juha Rinne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Research Center - Den Bosch</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Dautzenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Research Center - Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jort Vijverberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RICE - The Research Institute for the Care of Older People</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roy Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Clinical Research Facility</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Craig Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Dementia</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

